Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account…
As a Media Partner of the event, we invite you to take part in the 7th edition of PCI Days - a leading B2B trade fair for the pharmaceutical, cosmetics,…